Genzyme Corp. reported results of a Phase II/III study of its advanced phosphate binder (APB). Although the trial met its primary endpoint, which was to show that the APB lowered phosphate levels compared to placebo, the APB did not show a significant improvement in phosphate lowering compared to Genzyme’s Renvela.
As a result, the company is discontinuing further development of the drug. The company was looking to develop a product with higher potency that would more effectively bind phosphate, while maintaining all the benefits of Renvela.
Magazine
